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doi:10.1Objective: Matrix metalloproteinases participate in remodeling of extracellular matrix, which is central to the
development of aortic stenosis. Synthesis of certain matrix metalloproteinases is induced by the glycoprotein
extracellular matrix metalloproteinase inducer. We investigated whether extracellular matrix metalloproteinase
inducer and membrane-type 1 matrix metalloproteinase are abundant in calcific aortic valve and their role in the
pathogenesis of this condition.
Methods: Sixteen patients who underwent surgery for aortic stenosis (n¼ 12) or heart transplantation for ische-
mic cardiomyopathy (n ¼ 4) were reviewed. Expression of extracellular matrix metalloproteinase inducer and
membrane-type 1 matrix metalloproteinase proteins was assessed by Western blot (n ¼ 4 per group), immuno-
histochemistry for aortic stenosis (n¼ 12) and ischemic cardiomyopathy (n¼ 2), and in situ zymography (n¼ 3
per group). Functional relevance was investigated using an artificial valve model.
Results: Extracellular matrix metalloproteinase inducer and membrane-type 1 matrix metalloproteinase were
abundant in all stenotic valves. Control valves did not stain for either protein. Double immunofluorescence co-
localized extracellular matrix metalloproteinase inducer and membrane-type 1 matrix metalloproteinase to mac-
rophages. On Western blotting, both proteins were more abundant in stenotic valves than in control valves. In
situ zymography demonstrated greater gelatinolytic activity in stenotic valves than in control valves. Silencing
of the extracellular matrix metalloproteinase inducer gene using small interfering RNA reduced migration of
monocytes in an artificial valve model.
Conclusions: Extracellular matrix metalloproteinase inducer and membrane-type 1 matrix metalloproteinase
were demonstrated on macrophages in stenotic aortic valves, into which extracellular matrix metalloproteinase
inducer may promote monocyte immigration. The latter protein may therefore represent a potential target to
reduce the development of aortic stenosis. (J Thorac Cardiovasc Surg 2011;142:191-8)Aortic stenosis is the most commonvalvular heart disease in
Western countries1 and the most common indication for
aortic valve replacement.2 Up to a few years ago, aortic ste-
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Sbe solved by replacement surgery when severe symptoms
developed.
This view has changed recently. Calcific aortic stenosis is
no longer regarded as an immutable degenerative disease,
and research into measures aimed at slowing or even halting
the process has gathered speed.3 Inflammatory mechanisms
known to operate in atherosclerosis have been shown to op-
erate in degenerative aortic stenosis,4 albeit with some dif-
ferences5 so that calcific aortic stenosis is increasingly
regarded as an active inflammatory disease involvingmono-
cytes as the main cellular players.
Transmigration of monocytes into the subendothelium
is strongly associated with matrix metalloproteinases
(MMPs). Increased presence of MMP-2 and MMP-9
has been demonstrated in diseased tricuspid and bicuspid
aortic valves.6 Inflammation has been shown to be strongly
associated with calcium deposits in atherosclerosis and
aortic valve stenosis.7-9 In aortic valve myofibroblasts,
calcification mediated by the Wnt/LRP5/ß-catenin
signaling cascade is activated by oxidized low-density lipo-
protein and inhibited by statins.10 Further antiinflammatoryrdiovascular Surgery c Volume 142, Number 1 191
Abbreviations and Acronyms
ECM ¼ extracellular matrix
EMMPRIN ¼ extracellular matrix
metalloproteinase inducer
MMP ¼ matrix metalloproteinase
MT1-MMP ¼ membrane type 1-matrix
metalloproteinase
NFk-B ¼ nuclear factor kappa-B
siRNA ¼ small interfering RNA
SMC ¼ smooth muscle cell
TNF-a ¼ tumor necrosis factor alpha
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Seffects of statins include a decrease in the expression of
proinflammatory interleukin-1b in endothelial cells11 and
tumor necrosis factor (TNF)-a in macrophages,12 and
reduced proliferation of smooth muscle cells (SMCs).13
Statins have also been shown to prevent calcification of vas-
cular SMCs.14 In clinical trials, however, statins have thus
far failed to halt or regress aortic valve stenosis.15 There-
fore, a more nuanced view on the inflammatory process is
warranted.
Calcification is governed by complex interactions be-
tween the cellular components and the extracellular matrix
(ECM) of the aortic valve, with pathologic remodeling
resulting from an imbalance between synthesis and break-
down of ECM.
MMPs are known to play an important role in athero-
sclerotic plaque instability.16 De novo synthesis of cer-
tain metalloproteinases, such as MT1-MMP, MMP-2,
and MMP-9, is induced by the immunoglobulin-like gly-
coprotein extracellular matrix metalloproteinase inducer
(EMMPRIN) (also known as basigin or CD147).17 We
previously showed that EMMPRIN is up-regulated on
monocytes of patients with acute myocardial infarc-
tion.18 Moreover, atherogenic stimuli were shown to
up-regulate EMMPRIN protein expression on mono-
cytes, which in turn stimulated MMP-2 protein expres-
sion in SMCs.19
The present study investigated whether EMMPRIN is
abundant in the aortic valve, and if so, whether it may
contribute to the pathogenesis of calcific aortic stenosis.MATERIALS AND METHODS
Patients
Aortic valve fragments were collected from 16 patients undergoing sur-
gery for aortic stenosis (n ¼ 12) or heart transplantation for ischemic car-
diomyopathy (n ¼ 4). Valve fragments were used for histologic studies
(n ¼ 12 for aortic stenosis and n ¼ 2 for ischemic cardiomyopathy), and
when available, for Western blot analysis (n ¼ 4 for either group) and in
situ gelatin zymography (n ¼ 3 for either group).
The ethics committee approved the study protocol, and written,
informed consent was obtained from patients.192 The Journal of Thoracic and Cardiovascular SurgCells
Human MonoMac6 cells were cultured in VLE-RPMI-1640 (Biochrom,
Cambridge, UK) containing 10% low-tox fetal calf serum (Clonetics, San
Diego, Calif). MonoMac6 represents monocytic cells with a closely related
pattern of surface receptors andmonocyte- andmacrophage-like behavior.20
Human umbilical vein endothelial cells were purchased (Clonetics) and
cultured (for 2–4 passages) in low serum endothelial cell growth medium
(PromoCell, Heidelberg, Germany).
Protein Extraction
Valve leaflets were inserted in a 2 mol/L guanidinium chloride solution
containing 0.01 mol/L CaCl2, 0.2% Triton X-100, and 0.05 mol/L Tris–
HCl, pH 7.5 (3 mL/g wet weight) using a Polytron (Kinematica, Lucerne,
Switzerland) as previously described.21 After centrifugation (10,000g,
25 minutes, 48C), supernatants were dialyzed at 48C for 48 hours (Spec-
trapor membrane 6–8000 MWC; Spectrum Laboratories, Inc, Rancho
Dominguez, Calif). The dialyzed extracts were centrifuged (10,000g,
25 minutes, 48C), and protein concentration was determined by the
Bradford assay (Bio-Rad, Hercules, Calif).22
Western Blot
Western blot analysis was performed as previously described18 on aortic
valve tissues collected from patients undergoing aortic valve replacement
for aortic stenosis (n ¼ 4) or heart transplantation for ischemic cardiomy-
opathy (n¼ 4). After extraction and homogenization, identical protein con-
centrations of each sample were loaded per lane on 10% gels and subjected
to sodium dodecylsulfate polyacrylamide gel electrophoresis. Proteins
were blotted and probed with mouse monoclonal antibodies anti-human
EMMPRIN (HIM6, 10 mg/mL; Becton Dickinson, Franklin Lakes, NJ),
anti-humanMT1-MMP (clone 114-1F2, 10 mg/mL; Oncogene, Cambridge,
Mass), anti-human MMP-9 (polyclonal, 10 mg/mL; Millipore, Billerica,
Mass), anti-humanMMP-2 (clone 42-5D1, 10 mg/mL; Calbiochem, Darm-
stadt, Germany), or anti-human ß-actin (AC 15, 640 ng/mL; Sigma-
Aldrich, Munich, Germany). After they were washed, blots were incubated
with biotinylated secondary antimouse antibody (200 ng/mL; Santa Cruz
Biotechnology, Santa Cruz, Calif), and chemiluminescence staining was
performed by Western Blotting Luminol Reagent (Santa Cruz Biotechnol-
ogy), according to the manufacturer’s instructions.
Immunohistochemistry
Formalin-fixed and paraffin-embedded tissue was cut in 2-mm sections.
After antigen retrieval (cooking with citrate buffer at pH 6) and blocking
with 5% goat serum, slides were incubated with primary antibody solution
for 1 hour at room temperature. The following antibodies and concentrations
wereused:CD68 (phosphoglucomutase-1, 1:50;DAKO,Glostrup,Denmark),
EMMPRIN (1:200; abcam, Cambridge, Mass), MT1-MMP (1:200; abcam),
MMP-2 (1:100; abcam), and MMP-9 (1:100; abcam). Detection was carried
out using theDAKORealDetection kit following themanufacturer’s protocol.
For double immunofluorescence, Cy5-labeled goat anti-rabbit (Invitrogen,
Karlsruhe, Germany) and fluorescein isothiocyanate-labeled goat anti mouse
immunoglobulin-G (Invitrogen) were used.
In Situ Gelatin Zymography
In situ zymography was performed, as previously described,23 by incu-
bating cryosections (7 mm) with 40 mg/mL fluorescein-conjugated gelatin
(Invitrogen) in 50mmol/LTris-HCl pH 7.5, 10mmol/LCaCl2, 150mmol/L
NaCl, and 0.05 Triton X-100 (Sigma-Aldrich) for 24 hours at 37C. Sec-
tions were washed 3 times with phosphate-buffered saline and mounted
with Vectashield (BIOZOL, Eching, Germany). Gelatinase activity was vi-
sualized using fluorescent microscopy on an Olympus BX-50 microscope
(Center Valley, Pa). Cells were counterstained using Hoechst 33342 (Invi-
trogen). Specificity of gelatinolytic activity was confirmed by incubating
sections in the presence of EDTA/EGTA (20 mM) or the MMP inhibitor
GM6001 (Calbiochem) (1 mmol/L).ery c July 2011
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As an artificial valve model, a modified transmigration assay was
performed using the Cell Invasion Assay Kit (Millipore) as previously de-
scribed.24 In an invasion chamber, consisting of a 24-well tissue culture
plate with 12 cell culture inserts, a thin layer of Matrigel (ECMatrix,
Millipore) was dried over the inserts containing an 8-mm pore size polycar-
bonate membrane. TheMatrigel layer occludes themembrane pores. Endo-
thelial cells (human umbilical vein endothelial cells, PromoCell) were
placed over the Matrigel in a confluent manner. Afterward, human mono-
cytic cells (MonoMac6 cells, 2.5 3 105/mL) were placed into the upper
compartment of the transwells, either receiving control small interfering
(si)RNA or pretreated with EMMPRIN-silencing siRNA (Qiagen, Hilden,
Germany; EMMPRIN 2, target sequence GAC GGC CAT GCT GGT CTG
CAA [dXdY-overhang]). Medium containing fetal bovine serum was
introduced into the lower compartment beneath the filter. Subsequently,
monocytic cells were allowed to migrate through a layer of ECM, covered
by endothelial cells. After 48 hours, migrated MonoMac6 cells were
harvested from the lower surface of the membrane and subsequently
stained. Quantification was performed by colorimetric reading of optical
density at 560 nm.
Statistical Analysis
Results with normally distributed continuous variables were reported as
mean  standard deviation and analyzed by the Student unpaired t test.
Statistical analysis for in situ zymography fluorescence intensity was per-
formed using 1-way analysis of variance with post hoc Bonferroni multiple
comparisons procedure.FIGURE 1. EMMRIN and MT1-MMP in aortic stenosis. Representative
degenerative aortic valve tissue (left) and control aortic leaflet (center) are
shown. In arteriosclerotic valves, Elastica vanGieson staining demonstrates
a characteristic lesion with dense collagen (staining red), whereas control
patients exhibit loose connective tissue with subendothelial localization.
There is a clearly visible increase in CD68-positive macrophages and cells
demonstrating EMMPRIN and MT1-MMP compared with control leaflets.
In arteriosclerotic valves, the majority of cells demonstrate increased pro-
tein levels ofMMP-2 andMMP-9when comparedwith control tissue. Right
column demonstrates control stainings (positive controls: breast carcinoma
for EMMRIN (1), MT1-MMP (3), MMP-9 (7), and MMP-2 (9), and lymph
SRESULTS
Immunohistochemistry
Increased activity of MMPs has been demonstrated in
calcific aortic stenosis.4 EMMPRIN has been established
as a central activator of MMPs, increasing the secretion of
pro-MMPs and enhancing the expression of membrane-
type MMPs, such as MT1-MMP on the cell surface.
MT1-MMP facilitates migration of monocytes through ac-
tivated endothelial cells.25
To examine if EMMPRIN and MT1-MMP are expressed
in calcific aortic stenosis, immunohistochemical analysis
was performed on 12 stenotic valves containing degenera-
tive calcific tissue and on 2 noncalcified control valves.
All 12 stenotic valves stained positive for EMMPRIN,
MT1-MMP, MMP-9, MMP-2, and the macrophage marker
CD68, whereas neither of the controls did so for anymarker.
We used breast cancer as a control for positive EMMPRIN
and MT1-MMP staining. Staining of MT1-MMP,
EMMPRIN, MMP-2, and MMP-9 was highest in regions
of inflammation, in the border zone (leading edge) to calci-
fications. Measurement of positive staining area to the total
area demonstrated a value of 5% (2%). Macrophages
staining for EMMPRIN and MT1-MMP were mainly local-
ized within the layer of fibrosa (Figure 1).node for CD68 (5); subclass-matched irrelevant immunoglobulin-G served
as negative controls: (2, 4, 6, 8, 10). EMMPRIN-staining cells accumulate in
the border zone to calcification (*) (11), which is stained by alizarin red (12),
demonstrating that the changes in EMMPRIN activity occur in the calcific/
per-calcific regions of the valve. MTI-MMP, Membrane type 1-matrix
metalloproteinase; PGM, phosphoglucomutase.
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To confirm the immunohistologic results to localize
EMMPRIN and MT1-MMP, double immunofluorescence
staining was performed for EMMPRIN, MT1-MMP, andThe Journal of Thoracic and Cardiovascular Surgery c Volume 142, Number 1 193
FIGURE 2. Double immunofluorescence for EMMPRIN and MT1-MMP
in aortic valve tissue. Green fluorescence (fluorescein isothiocyanate) de-
notes tissue macrophage staining positive for CD68 (A, D), alpha smooth
muscle actin (G), and CD31 (J). Red fluorescence (Cy5) demonstrates cells
positive for EMMPRIN (B, H, K) and MT1-MMP (E). Double immunoflu-
orescence shows that EMMPRIN and MT1-MMP are co-expressed with
CD68 in altered aortic valves (C, F, arrows). This proves that infiltrating
macrophages in sclerotic valves express MT1-MMP and EMMPRIN.
Blue dye (Hoechst, Invitrogen, Karlsruhe, Germany) identifies nucleated
cells. EMMPRIN is not co-expressed with (a-SMA) (I), and EMMPRIN
colocalizes with CD31 (L, arrows). Right column represents negative con-
trol stainings for EMMPRIN (1), CD68 (2), MT1-MMP (3), a-SMA (4),
and CD31 (5). SMA, Smooth muscle actin.
FIGURE 3. Western blot immunoreactivity of EMMPRIN, MT1-MMP,
MMP-2, and MMP-9. Representative Western blot analysis of aortic valve
tissue demonstrates increased EMMPRIN (A), MT1-MMP (B), MMP-2
(C), and MMP-9 (D) protein level (to statistically significant extent,
P<.05) in aortic stenosis (left column) compared with control aortic valve
tissue (right column). ß-actin serves as control protein.MMP,Matrixmetal-
loproteinase.
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PRIN andMT1-MMP, showing that in the degenerative aor-
tic valve, activated macrophages express both EMMPRIN
and MT1-MMP on the cell surface. EMMPRIN
co-stained with CD31, a marker of endothelial cells, but
did not co-stain with a-smooth muscle actin, a marker of
activated valve interstitial cells (Figure 2).194 The Journal of Thoracic and Cardiovascular SurgBiochemical Analysis
These results prompted us to investigate the protein
expression of EMMPRIN, MT1-MMP, MMP-9, and
MMP-2. Western blot immunoreactivity of EMMPRIN,
MT1-MMP, MMP-9, and MMP-2 was detected in aortic
stenosis samples at a greater staining intensity than in
control aortic valve tissues (P<.05). ß-actin was used as
control protein (Figure 3).In Situ Gelatin Zymography
In situ gelatin zymography was performed to determine
whether increases in EMMPRIN or MT1-MMP, as demon-
strated by immunohistochemistry and Western blot, areery c July 2011
FIGURE 4. A, B, In situ gelatin zymography. Representative zymographs (A) of stenotic aortic valve (upper) demonstrate basic gelatinolytic activity. This
activity is dampened by the MMP inhibitor GM6001. In control aortic valves (lower) gelatinolytic activity is weak when compared with stenotic aortic
valves. Gelatinolytic specificity of activity is confirmed by incubating samples in the presence of EGTA. Exposure time: 200 ms. Intensity of the in situ
zymography fluorescencewas quantified using Quantity One software (Version 4.4.1) from BioRad (Hercules, CA). Data are shown (B) as mean standard
error of the mean of arbitrary fluorescence intensity (n ¼ 4). Basic gelatinolytic activity was significantly increased in stenotic aortic valves (control-
diseased) compared with non-diseased aortic valves (control-healthy) (*P< .05). Moreover, gelatinolytic activity was significantly dampened by the
MMP inhibitor GM6001 when compared with the basic gelatinolytic activity of the stenotic aortic valves (#P<.05). OD, Optical density; siRNA, small
interfering RNA; MMP, matrix metalloproteinase.
Joghetaei et al Evolving Technology/Basic Scienceassociated with local increases in MMP activity. In stenotic
aortic valve specimens, the basic gelatinolytic activity is in-
creased when compared with control aortic valves (P<.05,
n ¼ 4). This activity is dampened by the MMP inhibitor
GM6001 (P<.05, n ¼ 4) (Figure 4).E
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Enhanced protein expression of EMMPRIN and
MT1-MMP on monocytic cells in aortic stenosis led us to
investigate whether EMMPRIN was capable of affecting
transmigration of circulating monocytes into the subendo-
thelial space to foster the inflammatory process. For this,
an artificial valve model was used, composed of ECM cov-
ered by endothelial cells (human umbilical vein endothelial
cells). The EMMPRIN gene in human monocytic Mono-
Mac cells was silenced with EMMPRIN-silencing siRNAThe Journal of Thoracic and Cafor 48 hours, and cell transmigration through the recon-
structed artificial valve surface was studied. EMMPRIN-
silencing siRNA significantly reduced transmigration of
monocytic cells compared with pretreatment with control
siRNA (P<.05). A similar effect was demonstrated by pre-
treating monocytic cells with an MMP inhibitor (GM6001)
compared with control peptide (P<.05). For transmigration
of monocytic cells, EMMPRIN-specific siRNA had no fur-
ther effect when added to MMP inhibitor (GM6001)
(Figure 5).DISCUSSION
MMPs are involved in both the pathologic remodeling of
the left ventricle in patients with aortic valve stenosis26 and
the stenotic aortic valve tissue itself.6 Tumor cell-derived
EMMPRIN has been shown to regulate the activity ofrdiovascular Surgery c Volume 142, Number 1 195
FIGURE 5. A, B, Transmigration through an artificial valve surface quantitative analysis (A) and representative images from the transmigration studies
(B). Humanmonocytic MonoMac6 cells were treated with control siRNA or EMMPRIN-silencing siRNA for 48 hours, and their transmigration through the
composite of endothelial cell layer and Matrigel (Millipore, Billerica, Mass) was determined. EMMPRIN-silencing siRNA significantly reduced transmi-
gration of monocytic cells compared with pretreatment with control siRNA (*P<.05). A similar effect was demonstrated by pretreating monocytic cells
with theMMP inhibitor GM6001 (Calbiochem, Darmstadt, Germany) compared with control peptide (*P<.05). EMMPRIN-specific siRNA had no additive
effect to MMP inhibition for transmigration of monocytic cells (P ¼ .0621). NS, Not significant; OD, optical density.
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the membrane type 1 (MT1)-MMP has been regarded as
a major activator of soluble (pro-)MMPs, especially of
pro-MMP2.27
The current study shows that EMMPRIN andMT1-MMP
are increased in degenerative stenotic aortic valves com-
pared with normal control aortic valves. EMMPRIN local-
izes to monocytes and endothelial cells in aortic valve tissue
and provides evidence that inhibition of the EMMPRIN
gene may reduce migration of monocytes into the valve.
Immunohistochemistry and Western blot analysis con-
firmed previous data demonstrating an increase in MMP-2
and MMP-9 protein in calcified stenotic aortic valves, re-
flecting the presence of inflammation. Some, but not all,28
studies have indicated a potential involvement of MMP-2
in the development of aortic valve disease. MMP-2 was pre-
viously associated with tenascin-C, an ECM glycoprotein
found in developing bone and atherosclerotic plaque, in cal-
cific aortic valve stenosis. Moreover, the mRNA expression
and gelatinolytic activity of MMP-2 were up-regulated
when aortic valve interstitial cells were cultivated on colla-
gen supplemented with tenascin-C, thus supporting the
hypothesis that MMP-2 may be associated with progression
of calcification.29 Immunohistochemistry demonstrated
EMMPRIN in calcific degenerative specimens, a result
we confirmed using Western blotting. In histologic studies,196 The Journal of Thoracic and Cardiovascular SurgEMMPRIN was found in close proximity to CD68-positive
tissue macrophages and CD31-positive endothelial cells.
Double immune fluorescence staining co-localized
EMMPRIN with CD68 and CD31, suggesting that mono-
cytes entering the aortic valve and endothelial cells contain
EMMPRIN. Taken together, these findings suggest that
migration of monocytes into aortic valve tissue may be af-
fected by an EMMPRIN-based interaction of monocytes
and endothelial cells.
On the basis of observations in tumors30 and cardiovascu-
lar cells,18 EMMPRINmay induce proteolysis by activating
MMPs in calcific aortic valve stenosis and thus may influ-
ence the pathologic remodeling process. We are not aware
of prior data on EMMPRIN-mediated proteolytic effects
in calcific aortic valve stenosis, so our results represent
the first described association between EMMPRIN/MT1-
MMP and aortic valve stenosis. Our results are not sufficient
to prove that EMMPRIN plays a causal role in the develop-
ment of aortic stenosis in vivo. To draw such a conclusion, it
would be necessary to investigate its role in a good animal
model of aortic stenosis, something that has raised ques-
tions with regard to the extrapolation to humans.31 More-
over, in the mouse, knocking out the EMMPRIN gene has
usually proved lethal.32 Thus, a combination of these ap-
proaches is clearly beyond the scope of our investigation
at the present time. An indication of the potential functionalery c July 2011
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that EMMPRIN induces migration of macrophages across
a biological barrier resembling the endothelial cells lining
the aortic valve. Other EMMPRIN-mediated effects, such
as an increase in the production of MMP-2 and MMP-9
in the aortic valve, will also require evaluation in appropri-
ate models, as will the correlation of EMMPRIN activity
with the extent of calcification and the clinical outcome.
Other inflammatory sequelae may be caused by MMP-
mediated cleavage products, as has been demonstrated for
MMP-233 and MMP-934 in other disease entities, although
no studies exist regarding this mechanism in aortic stenosis.
Because protease activation in monocytes is linked to nu-
clear factor kappa-B (NFk-B) signaling, proinflammatory
downstream effects in aortic valve stenosis may involve
the NFk-B signaling cascade. We previously demonstrated
that cell–cell communication via EMMPRIN activates
NFk-B via the IkBa complex. In monocytes, NFk-B is
known to activate the synthesis of proinflammatory cyto-
kines, such as interleukin-6 and TNF-a. Pretreatment of
monocytes with an IKK inhibitor or EMMPRIN-specific
siRNA sharply hindered EMMPRIN-mediated cytokine
induction35; however, the implications of these data in the
setting of aortic valve stenosis remain to be clarified.
TNF-a may promote an osteoblast-like phenotype in hu-
man aortic valve myofibroblasts and thus at least partially
regulate the process of aortic valve calcification.36 It is
possible that EMMPRIN-overexpressing monocytes, by
secretion of TNF-a, are also capable of promoting an
osteoblast-like phenotype in aortic valve myofibroblasts
and thus contribute to calcification, but this is speculative
at the present time.
Little is known about EMMPRIN and MT1-MMP inter-
action in aortic valve tissues. Because constitutive EMM-
PRIN knockout models have proved lethal,32 developing
conditional knockout models may clarify EMMPRIN’s
role in the course of calcific aortic valve stenosis. Future
studies should focus on specific effects of EMMPRIN and
MT1-MMP on inflammation and calcification in aortic
valve stenosis and identify their particular contribution,
possibly by elaborating novel ligands for intracellular
activation cascades.
Limitation
Sample size is a major limiting factor for this study.
Nonetheless, we performed statistical analysis for the
Western blot results demonstrating significantly increased
protein levels of EMMPRIN and MT1-MMP in stenotic
aortic valves compared with control aortic valves.
CONCLUSIONS
The present study demonstrated both EMMPRIN and
MT1-MMP on macrophages in the stenotic aortic valve,
suggesting a pathway by which macrophages may induceThe Journal of Thoracic and Caproteolysis-mediated migration of macrophages into devel-
oping aortic valve stenosis. Silencing the EMMPRIN gene
using siRNA halted monocytic transmigration in an artifi-
cial valve model. These findings may assist in the develop-
ment of more nuanced anti-inflammatory strategies
inhibiting calcific and eventually degenerative sequelae in
aortic valve stenosis.
The authors thank Monika H€olderle and Renate Hegenloh for
expert technical assistance.References
1. Iung B, Baron G, Butchart EG, Delahaye F, Gohlke-Barwolf C, Levang OW,
et al. A prospective survey of patients with valvular heart disease in Europe:
The Euro Heart Survey on Valvular Heart Disease. Eur Heart J. 2003;24:
1231-43.
2. Babaliaros V, Block P. State of the art percutaneous intervention for the treatment
of valvular heart disease: a review of the current technologies and ongoing re-
search in the field of percutaneous valve replacement and repair. Cardiology.
2007;107:87-96.
3. Rosenhek R, Baumgartner H. Aortic sclerosis, aortic stenosis and lipid-lowering
therapy. Expert Rev Cardiovasc Ther. 2008;6:385-90.
4. Helske S, Kupari M, Lindstedt KA, Kovanen PT. Aortic valve stenosis: an active
atheroinflammatory process. Curr Opin Lipidol. 2007;18:483-91.
5. Miller JD, Chu Y, Brooks RM, Richenbacher WE, Pe~na-Silva R, Heistad DD.
Dysregulation of antioxidant mechanisms contributes to increased oxidative
stress in calcific aortic valvular stenosis in humans. J Am Coll Cardiol. 2008;
52:843-50.
6. Koullias GJ, Korkolis DP, Ravichandran P, Psyrri A, Hatzaras I, Elefteriades JA.
Tissue microarray detection of matrix metalloproteinases, in diseased tricuspid
and bicuspid aortic valves with or without pathology of the ascending aorta.
Eur J Cardiothorac Surg. 2004;26:1098-103.
7. Aikawa E, Aikawa M, Libby P, Figueiredo JL, Rusanescu G, Iwamoto Y, et al.
Arterial and aortic valve calcification abolished by elastolytic cathepsin S defi-
ciency in chronic renal disease. Circulation. 2009;119:1785-94.
8. Aikawa E, Nahrendorf M, Figueiredo JL, Swirski FK, Shtatland T, Kohler RH,
et al. Osteogenesis associates with inflammation in early-stage atherosclerosis
evaluated by molecular imaging in vivo. Circulation. 2007;116:2841-50.
9. Aikawa E, Nahrendorf M, Sosnovik D, Lok VM, Jaffer FA, Aikawa M, et al.
Multimodality molecular imaging identifies proteolytic and osteogenic activities
in early aortic valve disease. Circulation. 2007;115:377-86.
10. Rajamannan NM, Subramaniam M, Caira F, Stock SR, Spelsberg TC. Atorvasta-
tin inhibits hypercholesterolemia-induced calcification in the aortic valves via the
Lrp5 receptor pathway. Circulation. 2005;112:I229-34.
11. Inoue I, Goto S, Awata T, Mastunaga T, Kawai S, Nakijama T, et al. Lipophilic
HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of
MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and
p22phox by regulation of peroxisome proliferator-activated receptor alpha
(PPARalpha) in primary endothelial cells. Life Sci. 2000;67:863-76.
12. Rosenson RS, Tangney CC, Casey LC. Inhibition of proinflammatory cytokine
production by pravastatin. Lancet. 1999;353:983-4.
13. Laufs U, Marra D, Node K, Liao JK. 3-Hydroxy-3-methylglutaryl-CoA reduc-
tase inhibitors attenuate vascular smooth muscle proliferation by preventing
rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem. 1999;274:
21926-31.
14. Kizu A, Shioi A, Jono S, Koyama H, Okuno Y, Nishizawa Y. Statins inhibit in
vitro calcification of human vascular smooth muscle cells induced by inflamma-
tory mediators. J Cell Biochem. 2004;93:1011-9.
15. Chan KL, Teo K, Dumesnil JG, Ni A, Tam J, ASTRONOMER Investigators.
Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis:
results of the aortic stenosis progression observation: measuring effects of rosu-
vastatin (ASTRONOMER) trial. Circulation. 2010;121:306-14.
16. Newby AC.Metalloproteinase expression in monocytes and macrophages and its
relationship to atherosclerotic plaque instability. Arterioscler Thromb Vasc Biol.
2008;28:2108-14.
17. Biswas C, Zhang Y, DeCastro R, Guo H, Nakamura T, Kataoka H, et al. The
human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN)
is a member of the immunoglobulin superfamily. Cancer Res. 1995;55:434-9.rdiovascular Surgery c Volume 142, Number 1 197
Evolving Technology/Basic Science Joghetaei et al
E
T
/B
S18. Schmidt R, B€ultmann A, Ungerer M, Joghetaei N, B€ulb€ul €O, Thieme S, et al.
EMMPRIN regulates MMP activity in cardiovascular cells. Implications in acute
myocardial infarction. Circulation. 2006;113:834-41.
19. Schmidt R, Redecke V, Breitfeld Y, Wantia N, Miethke T, Massberg S, et al.
EMMPRIN (CD 147) is a central activator of extracellular matrix degradation
by Chlamydia pneumoniae-infected monocytes. Implications for plaque rupture.
Thromb Haemost. 2006;95:151-8.
20. May AE, Redecke V, Gr€uner S, Schmidt R,Massberg S, Miethke T, et al. Recruit-
ment of Chlamydia pneumoniae-infected macrophages to the carotid artery wall
in noninfected, nonatherosclerotic mice. Arterioscler Thromb Vasc Biol. 2003;
23:789-94.
21. Badier-Commander C, Verbeuren T, Lebard C, Michel JB, Jacob MP. Increased
TIMP/MMP ratio in varicose veins: a possible explanation for extracellular ma-
trix accumulation. J Pathol. 2000;192:105-12.
22. Bradford MM. A rapid and sensitive method for the quantitation of microgram
quantities of protein utilizing the principle of protein-dye binding. Anal Biochem.
1976;72:248-54.
23. Masson V, de la Ballina LR, Munaut C, Wielockx B, Jost M, Maillard C, et al.
Contribution of host MMP-2 and MMP-9 to promote tumor vascularization
and invasion of malignant keratinocytes. FASEB J. 2005;19:234-6.
24. Klouche M, May AE, Hemmes M, Messner M, Kanse SM, Preissner KT, et al.
Enzymatically modified, nonoxidized LDL induces selective adhesion and trans-
migration of monocytes and T-lymphocytes through human endothelial cell
monolayers. Arterioscler Thromb Vasc Biol. 1999;19:784-9.
25. Sithu SD, English WR, Olson P, Krubasik D, Baker AH, Murphy G, et al. Mem-
brane-type 1-matrix metalloproteinase regulates intracellular adhesion molecule-
1 (ICAM-1)-mediated monocyte transmigration. J Biol Chem. 2007;282:25010-9.
26. Fielitz J, Leuschner M, Zurbr€ugg HR, Hannack B, Pregla R, Hetzer R, et al. Reg-
ulation of matrix metalloproteinases and their inhibitors in the left ventricular
myocardium of patients with aortic stenosis. J Mol Med. 2004;82:809-20.
27. Sounni NE, Devy L, Hajitou A, Frankenne F, Munaut C, Gilles C, et al.
MT1-MMP expression promotes tumor growth and angiogenesis through an
up-regulation of vascular endothelial growth factor expression. FASEB J. 2002;
16:555-64.198 The Journal of Thoracic and Cardiovascular Surg28. Parolari A, Loardi C, Mussoni L, Cavallotti L, Camera M, Biglioli P, et al. Non-
rheumatic calcific aortic stenosis: an overview from basic science to pharmaco-
logical prevention. Eur J Cardiothorac Surg. 2009;35:493-504.
29. Jian B, Jones PL, Li Q, Mohler ER 3rd, Schoen FJ, Levy RJ. Matrix
metalloproteinase-2 is associated with tenascin-C in calcific aortic stenosis.
Am J Pathol. 2001;159:321-7.
30. Sameshima T, Nabeshima K, Toole BP, Yokogami K, Okada Y, Goya T, et al. Gli-
oma cell extracellular matrix metalloproteinase inducer (EMMPRIN) (CD147)
stimulates production of membrane-type matrix metalloproteinases and activated
gelatinase A in co-cultures with brain-derived fibroblasts.Cancer Lett. 2000;157:
177-84.
31. Hekimian G, Passefort S, Louedec L, Houard X, Jacob MP, Vahanian A, et al.
High-cholesterol þ vitamin D2 regimen: a questionable in-vivo experimental
model of aortic valve stenosis. J Heart Valve Dis. 2009;18:152-8.
32. Igakura T, Kadomatsu K, Kaname T,Muramatsu H, Fan QW,Miyauchi T, et al. A
null mutation in basigin, an immunoglobulin superfamily member, indicates its
important roles in peri-implantation development and spermatogenesis. Dev
Biol. 1998;194:152-65.
33. Reinboldt S, Wenzel F, Rauch BH, Hohlfeld T, Grandoch M, Fischer JW, et al.
Preliminary evidence for a matrix metalloproteinase-2 (MMP-2)-dependent
shedding of soluble CD40 ligand (sCD40L) from activated platelets. Platelets.
2009;20:441-4.
34. Menchen L, Marın-Jimenez I, Arias-Salgado EG, Fontela T, Hernandez-
Sampelayo P, Rodrıguez MC, et al. Matrix metalloproteinase 9 is involved in
Crohn’s disease-associated platelet hyperactivation through the release of soluble
CD40 ligand. Gut. 2009;58:920-8.
35. Schmidt R, B€ultmann A, Fischel S, Gillitzer A, Cullen P, Walch A, et al. Extra-
cellular matrix metalloproteinase inducer (CD147) is a novel receptor on plate-
lets, activates platelets, and augments nuclear factor kappaB-dependent
inflammation in monocytes. Circ Res. 2008;102:302-9.
36. Kaden JJ, Kilic¸ R, Sarikoc¸ A, Hagl S, Lang S, Hoffmann U, et al. Tumor necrosis
factor alpha promotes an osteoblast-like phenotype in human aortic valve myofi-
broblasts: a potential regulatory mechanism of valvular calcification. Int J Mol
Med. 2005;16:869-72.ery c July 2011
